GSK Secures EU & Japanese Approvals For Shingrix
Executive Summary
Hot on the heels of the FDA approval, GlaxoSmithKline has received the green light for its shingles vaccine Shingrix from both the EU Commission and the Japanese Ministry of Health, Labour and Welfare but it is remaining tightlipped about its commercialization plans.
You may also be interested in...
Shingrix Seen Replacing Zostavax In EU & US as Shingles Standard Of Care
Shingrix is likely to replace Merck & Co's Zostavax as the preferred shingles vaccine in the EU and US, following the GSK product’s approval in the US and recent positive opinion in the EU. Sales in major markets could approach $700m by 2025.
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.